Peptid-Klartext DE Community
Weight loss & metabolism

Tesofensine: Effects, Evidence and Risks

Research use only: Tesofensin is not approved as a medicine. It is offered as a research substance labelled “for research purposes only – not for use in humans or animals”. This page summarises the state of research and is not a recommendation to use it.

Also known as NS2330.

StatusNot approved
EvidenceLarge studies
Drug classTriple monoamine reuptake inhibitor · tablet
Add as vial in tracker

We only show doses for approved medicines according to the prescribing information – in the calculator.

What is Tesofensine?

Not a peptide but a drug that inhibits the reuptake of dopamine, noradrenaline and serotonin in the brain. This suppresses appetite; it was originally developed for Parkinson's and Alzheimer's disease.

How well studied is Tesofensine?

Phase 2 trial TIPO-1: around 10 % weight loss in 24 weeks. A phase 3 trial in Mexico with 372 participants showed similar results. Large long-term studies on cardiovascular safety are lacking.

What side effects and risks does Tesofensine have?

As a centrally acting substance that affects noradrenaline, increases in heart rate and blood pressure, sleep problems, dry mouth and mood or psychiatric effects are to be expected. Long-term cardiovascular safety data are lacking; interactions with antidepressants and other stimulants are possible.

Is Tesofensine approved in Germany?

In short: no. Not approved anywhere: in Mexico the authority COFEPRIS initially rejected the application in 2024, and it was resubmitted in 2025. Per the 2026 WADA list it is prohibited in competition as a stimulant (S6.B). Not legally marketable in Germany; online products are untested.

Sources

Note: We deliberately do not list any doses here. For approved medicines, your doctor sets the dose; for unapproved substances there is no reliable information.